 That can be a weakness. Because, of course, as an investor, you're thinking, well, at least I know they've got this huge safety net of billions and billions of cash set aside. But, in fact, one of the lines from the book, wealth, you know, shirtsleeves to shirtsleeves in a few generations, that having too much money actually can create a lot of problems and bad incentives inside that system. I'm convinced this is at the heart of the R&D drought in big pharma.